|
|
Blood, 15 February 2006, Vol. 107, No. 4, pp. 1391-1396.
Prepublished online as a Blood First Edition Paper on November 1, 2005; DOI 10.1182/blood-2005-07-2669.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Gene-expression patterns predict phenotypes of immune-mediated thrombosis
Anil Potti,
Andrea Bild,
Holly K. Dressman,
Deborah A. Lewis,
Joseph R. Nevins, and
Thomas L. Ortel
From the Department of Medicine, Division of Hematology, Duke University Medical Center; the Duke Institute for Genome Sciences and Policy; the Department of Molecular Genetics and Microbiology, Duke University; and the Duke Hemostasis and Thrombosis Center, Durham, NC.
Antiphospholipid antibody syndrome (APS) is a complex autoimmune thrombotic disorder with defined clinical phenotypes. Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complications, the severity of these potential events mandates aggressive and extended lifelong anti-thrombotic therapy. One hundred twenty-nine patients (57 patients with APS and venous thromboembolism [VTE], 32 patients with VTE without aPLA, 32 patients with aPLA only, and 8 healthy patients) were enrolled. RNA from peripheral-blood collection was used for DNA microarray analysis. Patterns of gene expression that characterize APS as well as thrombosis in the presence of aPLA were identified by hierarchical clustering and binary regression methods. Gene-expression profiles identify and predict individuals with APS from patients with VTE without aPLA. Importantly, similar methods identified expression profiles that accurately predicted those patients with aPLA at high risk for thrombotic events. All profiles were validated in independent cohorts of patients. The ability to predict APS, but more importantly, those patients at risk for venous thrombosis, represents a paradigm for a genomic approach that can be applied to other populations of patients with venous thrombosis, providing for more effective clinical management of disease, while also reflecting the possible underlying biologic processes.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Genomics and targeting antithrombotic therapy in antiphospholipid syndrome
- Michael Greaves
Blood 2006 107: 1249.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
J. Lohrmann and R. C. Becker
New Anticoagulants -- The Path from Discovery to Clinical Practice
N. Engl. J. Med.,
June 26, 2008;
358(26):
2827 - 2829.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Becker
Emerging Paradigms, Platforms, and Unifying Themes in Biomarker Science
J. Am. Coll. Cardiol.,
October 30, 2007;
50(18):
1777 - 1780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Learn, P. E. Fecci, R. J. Schmittling, W. Xie, I. Karikari, D. A. Mitchell, G. E. Archer, Z. Wei, H. Dressman, and J. H. Sampson
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T Cells in Patients with Malignant Glioma Reveals Differential Expression of the Immunologic Transcriptome Compared with T Cells from Healthy Volunteers
Clin. Cancer Res.,
December 15, 2006;
12(24):
7306 - 7315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Mahaffey and R. C. Becker
The Scientific Community's Quest to Identify Optimal Targets for Anticoagulant Pharmacotherapy
Circulation,
November 28, 2006;
114(22):
2313 - 2316.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Mandel and A Achiron
Gene Expression Studies in Systemic Lupus Erythematosus
Lupus,
July 1, 2006;
15(7):
451 - 456.
[Abstract]
[PDF]
|
|
|
| |
